Shunsuke Kiuchi

Dr. Shunsuke Kiuchi

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2017 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
SKShunsuke Kiuchi
Shunsuke Kiuchi
SHShinji Hisatake
Shinji Hisatake
TKTakayuki Kabuki
Takayuki Kabuki
TOTakashi Oka
Takashi Oka
SDShintaro Dobashi
Shintaro Dobashi
TITakanori Ikeda
Takanori Ikeda

2 February 2020 in Clinical and Experimental Hypertension
Verified
Journal Article
Closed access
SKShunsuke Kiuchi
Shunsuke Kiuchi
SHShinji Hisatake
Shinji Hisatake
TKTakayuki Kabuki
Takayuki Kabuki
TOTakashi Oka
Takashi Oka
SDShintaro Dobashi
Shintaro Dobashi
TITakanori Ikeda
Takanori Ikeda
β blockers (BBs) play an important role in heart failure (HF) treatment. However, orthostatic hypotension (OH) is sometimes caused by BBs. The bisoprolol transdermal patch works more slowly and is long acting compared with the bisoprolol fumarate tablet. The risk of OH may be reduced by using the bisoprolol transdermal patch. We evaluated 57 consecutive patients who were taking the bisoprolol fumarate tablet for chronic HF with hypertension from November 2016 to September 2017. We switched the patients to the bisoprolol transdermal patch. Because 12 of 57 subjects could not continue using the bisoprolol transdermal patch, we analyzed the remaining 45 patients. We investigated BP, blood tests, and changes in BP from supine to standing positions before and after 6 months of switching from tablet to patch. OH was diagnosed by observing a systolic/diastolic BP drop of at least 20/10 mmHg or an absolute systolic BP (sBP) of <90 mmHg from the standing position. No significant changes were observed in the BP and BPs from supine to standing positions, whereas log brain natriuretic peptide was significantly reduced after switching from patch to tablet (2.102 to 2.070pg/dl, P = .039). OH, which occurred in originally 17 patients, showed improvement and eventually appeared in 4 patients. In these patients, changes in BP from supine to standing positions were also significantly improved (changes in sBP, −11 to −6mmHg, P = .016). This study demonstrated that switching from the bisoprolol fumarate tablet to transdermal patch reduced the morbidity of OH in HF patients.

26 May 2020 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
TSTakahide Sano
Takahide Sano
SKShunsuke Kiuchi
Shunsuke Kiuchi
SHShinji Hisatake
Shinji Hisatake
TKTakayuki Kabuki
Takayuki Kabuki
TOTakashi Oka
Takashi Oka
TITakanori Ikeda
Takanori Ikeda

15 February 2019 in Internal Medicine
Verified
Journal Article
Open access
PDF file
SKShunsuke Kiuchi
Shunsuke Kiuchi
TITakanori Ikeda
Takanori Ikeda
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

17 May 2017 in Clinical and Experimental Hypertension
Verified
Journal Article
Closed access
SKShunsuke Kiuchi
Shunsuke Kiuchi
SHShinji Hisatake
Shinji Hisatake
TKTakayuki Kabuki
Takayuki Kabuki
TOTakashi Oka
Takashi Oka
SDShintaro Dobashi
Shintaro Dobashi
TITakanori Ikeda
Takanori Ikeda
Background: The optimal therapy in patients with heart failure preserved ejection fraction (HFpEF) and hypertension (HT) has not been revealed. The beta blocker (BB) and the renin angiotensin aldosterone system inhibitor (RAAS-I) are recommend as class IIa in patients with HFpEF. The calcium channel blocker (CCB), a major anti-hypertensive drugs in Japan, is also recommend as class IIa in patients with HFpEF. However, the difference between azelnidipine, an L type CCB, and cilnidipine, an N type CCB, is unclear. We investigated the difference between azelnidipine and cilnidipine in patients with HFpEF and HT. Methods: Twenty-five consecutive HFpEF patients treated with BB and RAAS-I from April 2013 to March 2015 were enrolled. Initially, cilnidipine was used, and then switched to azelnidipine. Age, gender, blood pressure (BP), heart rate (HR), blood tests, echocardiography, and cardiac-scintigraphy (123I-metaiodobenzylguanidine: MIBG) were measured before and after six months from azelnidipine administration. Results: There was no statistically significant difference in BP. B type natriuretic peptides were significantly reduced (pre-state: 195.4 ± 209.7 pg/ml and post-state: 140.7 ± 136.4 pg/ml, p = 0.050). In echocardiography, the TEI index tended to be decreased (pre-state: 0.47 ± 0.15 and post-state: 0.42 ± 0.08, p = 0.057). As for MIBG, there was no significant change in the heart/mediastinum ratio. However, the washout rate was significantly reduced (pre-state: 44.7 ± 12.2 and post-state: 40.7 ± 12.1, p = 0.011). In addition, there was no statistically significant change, although HR tended to decrease by switching to azelnidipine (pre-state: 62.7 ± 11.6 and post-state: 61.8 ± 16.5, p = 0.373). Conclusions: In patients with HT and HFpEF, azelnidipine improved the severity of HF and cardiac sympathetic nerve activity compared with cilnidipine.

1 June 2022 in Journal of Cardiology
Verified
Journal Article
Closed access
SKShunsuke Kiuchi
Shunsuke Kiuchi
TITakanori Ikeda
Takanori Ikeda